Paradigm Biopharmaceuticals Limited reported earnings results for the half year ended December 31, 2022. For the half year, the company reported sales was AUD 0.00471 million compared to AUD 0.0452 million a year ago. Net loss was AUD 31.87 million compared to AUD 26.99 million a year ago.

Basic loss per share from continuing operations was AUD 0.1129 compared to AUD 0.118 a year ago. Diluted loss per share from continuing operations was AUD 0.1129 compared to AUD 0.118 a year ago.